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Supplemental Table S1: monitored ion transitions 
Analyte Parent Ion Product Ion(s) 
d4-cholesteryl oleate (internal standard) 672.635 369.400 
d7-cholesteryl oleate 675.679 376.400 
d16-cholesteryl oleate 684.735 376.400 
d17-LKM38 oleate (internal standard) 723.600 407.300 
LKM38 oleate 706.600 407.300 
d9-LKM38 oleate 715.600 407.300 
d5-cholestenone (internal standard) 530.600 126.100, 389.460 
d7-cholestenone 532.600 126.100, 391.480 






















Supplemental Table S2: Immunoprecipitation and western blotting conditions 
 
 
Beads: DynabeadsTM Protein A (Novex) 
TBS-T: 140 mM NaCl, 3 mM KCl, 25 mM Tris Base, 0.05% Tween-20, pH 7.4 
Secondary incubations were performed at 1:10,000 using anti-Rabbit-HRP (Jackson Immuno) or anti-Chicken-HRP 















Target Antibody IP WB 
NPC1 Millard et al., JBC 2000, 
275:38445 
1.5 µg /50 µL beads 
Overnight incubation 




1.5 µg/50 µL beads 
Overnight incubation 






4 µg/50 µL beads, BS3 crosslinked 
3 hour incubation 






4 µg/50 µL beads 
3 hour incubation 





Not applicable 1:10000 in 5% milk TBS-T 
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SUPPLEMENTAL METHODS 






1: R1 = O; R2 = OH; R3 = O
2: R1 = O; R2 = OTBDMS; R3 = O






4: R1 = OH; R2 = b-OAc, a-H 
5: R1 = OMOM; R2 = b-OAc, a-H 
6: R1 = OMOM; R2 = b-OH, a-H 
7: R1 = OMOM; R2 = O











9 10: R = CO2Et
11: R = CH2OH
12: R = CH2OMs





14: R = OH
15: R = O








17 18: R = OMOM









(17β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-17-hydroxy-androst-5-en-3-one (3).   To a stirred cold (10 °C) 
solution of steroid 2 (12.5 g, 30 mmol) in EtOH (100 mL) and THF (10 mL) was added dropwise a solution of NaBH4 (304 
mg, 8 mmol, 0.27 eq) in EtOH (20 mL). The reaction was slowly warmed to –5 °C and then to 0 °C while the reaction was 
monitored by TLC.  After 4 h, the reaction was acidified by adding saturated aqueous NH4Cl. The EtOH and THF were 
removed under reduced pressure to give a residue. Water was added and the product was extracted into CH2Cl2. The 
combined extracts were washed with brine, dried over anhydrous Na2SO4 and the solvent removed to give a viscous liquid 
which was purified by flash column chromatography (silica gel eluted with 10-20% EtOAc in hexane) to yield steroid 3 as 
a solid (8.7g, 69%) which had: 1H NMR(400 MHz, CDCl3) δ 5.84 (s, 1H), 3.87 (dd, J = 11. 2 Hz, J = 9.8 Hz, 2H), 3.61 (t, 
 5 
J = 6.4Hz, 1H), 0.83 (s, 9H), 0.77 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR(100 MHz, CDCl3) δ  200.2, 178.1, 125.8, 
81.4, 65.7, 54.1,50.9, 43.6, 42.8, 36.8, 36.3, 34.8, 33.6, 33.3, 31.5, 30.3, 25.7, 23.2, 21.2, 17.9, 11.2, –5.8, –5.9. 
(3β,17β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-androst-5-ene-3,17 diol, 17-acetate (4).   To a cold (0 °C) stirred 
mixture of steroid 3 (4.5 g, 11 mmol), NaI (5 g, 33 mmol) and acetic anhydride (25 mL) was added trimethylchlorosilane 
(4 ml, 32 mmol) and the reaction was warmed to room temperature and stirred for 15 h. The reaction was diluted with 
hexane (250 mL) and stirred. The hexane layer was decanted and added to a cold solution of triethylamine (15 mL):hexane 
(200 mL) and stirred for 10 min. To the cold solution was added aqueous NaHCO3 solution (200 mL) and stirring was 
continued for 40 min. The biphasic mixture was transferred to a separatory funnel and the hexane layer was separated. The 
aqueous solution was extracted with EtOAc (2 x 60 mL) and the combined organic extracts were dried over Na2SO4 and the 
solvents removed under reduced pressure to give an oil. The crude product was immediately purified by flash column 
chromatography to give the intermediate 3,5-diene,-3,17-diacetate (5.0 g, 90%), which was immediately converted to steroid 
4. 
 
To the 3,5-diene-3,17diacetate (5.0 g, 9.9 mmol) in EtOH (50 mL) and THF (5 mL) was added NaBH4 (950 mg, 25 mmol) 
in portions over a period of 30 min and the reaction was allowed to stir at room temperature for 17 h.  The reaction was 
acidified by adding saturated aqueous NH4Cl and the product was extracted into CH2Cl2. The CH2Cl2 was washed with 
brine, dried over anhydrous Na2SO4 and the solvents removed under reduced pressure to give a viscous oil. The crude 
product was purified by flash column chromatography (silica gel eluted with 15-25% EtOH in hexane) to give steroid 4 
(3.25 g, 65%) which had:  1H NMR(400 MHz, CDCl3)  δ 5.40 (b s, 1H), 4.58 (t, J = 8.2 Hz, 1H), 3.74 (d, J = 10.5 Hz, 1H) 
3.57 (d, J = 10.5 Hz, 1H), 3.54 (m, 1H), 2.03 (s, 3H), 0.87 (s, 9H), 0.83 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR(100 
MHz, CDCl3) δ  171.2, 136.7, 124.7, 82.8, 71.4, 63.1, 51.6, 50.4, 42.6, 42.5, 41.3, 37.1, 32.7, 32.5, 31.9, 31.1, 27.5, 25.8, 
23.5, 21.3, 21.1, 18.1, 12.20, –5.63, –5.66. 
 
 (3β,17β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-androst-5-en-17 ol, 17-acetate (5).  To a 
cold solution (0 °C) of steroid 4 (4.63 g, 10 mmol), Hunig’s base (5.2 ml, 30 mmol) and CH2Cl2 (40 mL) was added 
chloromethyl methyl ether (1.52 ml, 20 mmol) and the reaction was warmed to room temperature and stirred for 12 h. The 
reaction was quenched by adding saturated aqueous NaHCO3 solution and the product extracted into CH2Cl2. The CH2Cl2 
was washed with brine, dried over anhydrous Na2SO4 and the solvents removed under reduced pressure. The crude product 
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was purified by flash column chromatography (silica gel eluted with 10-15% EtOAc in hexane to give steroid 5 (4.86g, 
96%) which had: 1H NMR(400 MHz, CDCl3) δ 5.55 (b s, 1H), 4.69 (s, 2H), 4.59 (t, J = 8.2Hz, 1H), 3.75 (d, J = 10.6 Hz, 
1H), 3.59 (d, J = 10.9 Hz, 1H),  3.46 (m, 1H), 3.37 (s, 3H), 2.04 (s, 3H), 0.88 (s, 9H), 0.84 (s, 3H), 0.04 (s, 3H), 0.03 (s, 
3H); 13C NMR(100 MHz, CDCl3) δ 171.3, 136.6, 124.9, 94.7, 82.8, 76.6, 63.1, 55.2, 51.6, 50.4, 42.6, 41.5, 39.9, 37.1, 32.7, 
32.5, 31.11, 29.3, 27.6, 25.8, 23.5, 21.3, 21.2, 18.1, 12.2, –5.61, –5.64. 
 
(3β,17β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-androst-5-en-17 ol (6).  A mixture of steroid 
5 (4.05 g, 8 mmol), K2CO3 (1.28g, 10 mmol) and MeOH (25 ml) was heated at reflux for 2h. The reaction mixture was 
cooled and the MeOH was removed under reduced pressure to give a solid. Water (200 mL) was added and the product was 
extracted into CH2Cl2. The CH2Cl2 was washed with brine, dried over anhydrous Na2SO4 and the solvents removed under 
reduced pressure. The residue was purified by flash column chromatography (silica gel eluted with 20-35% EtOAc in 
hexane) to give steroid 6 (3.6 g, 97%) which had:  1H NMR(400 MHz, CDCl3) δ 5.55 (b s, 1H), 4.69 (s, 2H), 3.76 (d, J = 
10.4 Hz, 1H), 3.61 (m, 2H), 3.46 (m, 1H), 3.37 (s, 3H), 0.88 (s, 9H), 0.78 (s, 3H), 0.04 (s, 3H), 0.03  (s, 3H); 13C NMR(100 
MHz, CDCl3) δ 136.6, 124.9, 94.6, 81.7, 76.6, 63.1, 55.2, 51.9, 50.6, 42.9, 41.5, 39.9, 36.9, 32.7, 32.7, 31.1, 30.4, 29.3, 
25.8, 23.4, 21.4, 18.1, 11.2, –5.62 (2 X C). 
 
(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-androst-5-en-17 one (7).  To a stirred solution of 
steroid 6 (3.25 g, 7 mmol) in CH2Cl2 (25 mL), was added pyridinium chlorochromate (3.02 g, 14 mmol) in portions and the 
reaction was stirred for 6 h. The reaction mixture was diluted with hexane (150 mL) and the supernatant solution was passed 
through a silica gel column eluted with hexane and then by 10-20% EtOAc in hexane. After solvent removal under reduced 
pressure, steroid 7 (2.95 g, 91%) was obtained as a colorless solid which had:  1H NMR(400 MHz, CDCl3) δ 5.60 (b s, 1H), 
4.69 (s, 2H), 3.80 (d, J = 11 Hz, 1H), 3.61 (d, J = 11 Hz, 1H), 3.46 (m, 1H), 3.38 (s, 3H), 0.92 (s, 3H), 0.87 (s, 9H), 0.04 (s, 
3H), 0.03 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 221.4, 136.7, 124.6, 94.7, 76.5, 63.3, 55.2, 52.4, 50.6, 47.8, 41.6, 39.9, 
35.8, 33.0, 32.4, 31.8, 30.4, 29.3, 25.8 (3 X C), 21.8, 21.0, 18.2, 14.2, 13.9, –5.57 (2 X C). 
(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-pregna-5,17(20)-dien-21-oic acid, ethyl ester 
(8). To a warm (40 °C) mixture of steroid 7 (2.8 g, 6 mmol), triethyl phosphonoacetate (5.9 mL, 30 mmol) in EtOH (100 
mL) was added a solution of sodium ethoxide in EtOH (690 mg sodium in 12 mL of ethanol, 30 mmol) dropwise over a 
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period of 10 min. The reaction mixture was heated at reflux for 18 h. The reaction mixture was cooled and the ethanol was 
removed under reduced pressure and the residue was cooled in an ice-water bath and neutralized by adding aqueous 6N 
HCl. The mixture was further diluted with water (150 mL) and extracted with EtOAc (3 x 100 mL). The combined organic 
extracts were dried over anhydrous Na2SO4 and the solvents removed under reduced pressure to give an off-white solid. 
The crude product was purified by flash column chromatography (silica gel eluted with 10-20% EtOAc in hexane to give 
steroid 8 as a white solid (3.0 g, 95%) which had: 1H NMR (400 MHz, CDCl3) δ 5.58 (b s, 1H, m), 5.54 (t, J = 2.2 Hz, 1H), 
4.69 (s, 2H), 4.15 (q, J = 7.0 Hz, 2H),   3.78 (d, J = 10.6 Hz, 1H), 3.61 (d, J = 10.6 Hz, 1H), 3.43 (m, 1H),  3.38 (s, 3H), 
2.82 (m, 2H), 1.28 (t, J = 7.0 Hz, 3H), 0.87 (s, 9H), 0.87 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
176.5, 167.5, 136.6, 124.9, 108.4, 94.7, 76.6, 63.2, 59.5, 55.2, 54.5, 50.6, 46.3, 41.6, 39.9, 35.5, 32.8, 32.4, 31.3, 30.4, 29.3, 
25.8 (3 X C), 24.40, 21.65, 18.52, 18.15, 14.38, –5.59, –5.60.  
(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-pregna-5-en-21-oic acid, ethyl ester (9).   A 
mixture of steroid 8 (2.66 g, 5 mmol), 5% Pt-C (70 mg) in EtOH (100 mL) was hydrogenated in a Parr hydrogenation 
apparatus at 20 psi H2. The reaction was stopped every half-hour and checked by TLC for the disappearance of steroid 8 by 
loss of its UV on the TLC plate. The reaction was run for about 3 h. The crude reaction mixture was loaded on a silica gel 
column and eluted with 40% EtOAc in hexane to give an inseparable mixture of steroid 9 containing ca.10% of a steroid in 
which the Δ5-double bond had also been reduced (2.6 g). The following bromination, chromatography, debromination 
sequence was used to separate the two steroid products. 
To crude a mixture of crude steroid product 9 (2.6 g, 4.9 mmol) and NaOAc (1.64 g, 20 mmol) in diethyl ether (100 mL) 
was added dropwise bromine (0. 36 mL, 7 mmol) dissolved in acetic acid (8 mL) and the reaction was stirred for 20 min. 
The reaction was quenched with 5% aqueous sodium thiosulfate solution (20 mL) followed by careful addition of aqueous 
saturated NaHCO3 (100 mL). After stirring for 10 min, the biphasic reaction mixture was transferred to a separatory funnel 
and the organic layer was separated. The aqueous layer was extracted with CH2Cl2. The combined organic extracts were 
dried over anhydrous Na2SO4 and the solvents removed under reduced pressure to give an oil. Flash column chromatography 
(silica gel eluted with 5-20% EtOAc in hexane) yielded two dibromides along with the readily removed non-brominated 
steroid in which the Δ5-double bond had been reduced. The less polar 5α,6β-dibromide was obtained as an oil (1.73 g, 50%) 
which had: 1H NMR (400 MHz, CDCl3) δ 4.80 (b s, 1H), 4.71 (s, 2H), 4.36 (m, 1H), 4.31 (d, J = 10.6 Hz, 1H), 4.12 (q, J = 
7 Hz, 1H), 3.97 (d, J = 11 Hz, 1H), 3.39 (s, 3H), 1.26 (t, J = 7 Hz, 3H), 0.90 (s, 9H), 0.66 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H). 
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The more polar 5β,6α-dibromide was obtained as an oil (1.04 g, 30%) which had: 1H NMR (400 MHz, CDCl3) δ 5.56 (m, 
1H), 4.78 (d, J = 7 Hz, 1H), 4.63 (d, J = 7 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 4.04 (b s, 1H), 3.95 (d, J = 11.4 Hz, 1H), 3.78 
(d, J = 7 Hz, 1H), 3.41 (s, 3H), 2.86 (d, J = 16.4 Hz, 1H), 1.26 (t, J = 7 Hz, 1H), 0.93 (s, 9H), 0.64 (s, 3H), 0.14 (s, 3H), 0.10 
(s, 3H).  
The two bromides were combined (2.77 g, 4 mmol), dissolved in acetic acid (10 mL) and EtOAc (30 mL), zinc dust (1.3 g, 
20 mmol) was added and the reaction was vigorously stirred at room temperature for 2 h. The reaction was filtered through 
a funnel fitted with cotton plug, and the filter-cake was washed with EtOAc. The combined filtrate and washings were 
stirred in a round-bottom flask and the acetic acid was carefully neutralized by adding saturated aqueous NaHCO3. The 
layers were separated and the aqueous phase was extracted with EtOAc. The combined organic layers were dried over 
anhydrous Na2SO4 and the solvent removed under reduced pressure to give an off-white solid. Purification by flash column 
chromatography (silica gel eluted with 10-25% EtOAc in hexane) yielded steroid 9 (2.0 g, 95%) which had: 1H NMR(400 
MHz, CDCl3) δ 5.56 (b s, 1H), 4.69  (s, 2H), 4.12 (q, J = 7.5 Hz, 2H), 3.75 (d, J = 10.6 Hz, 1H), 3.59 (d, J = 10.9 Hz, 1H), 
3.46 (m, 1H), 3,38 (s, 3H), 1.26 (t, J = 7.0 Hz, 3H), 0.87 (s, 9H), 0.65 (s, 3H), 0.3 (s, 3H), 0.02 (s, 3H); 13C NMR(100 MHz, 
CDCl3) δ 174.0, 136.6, 125.1, 94.6, 76.7, 63.1, 60.1, 56.2, 55.2, 50.7, 46.8, 42.1, 41.6, 39.9, 37.6, 35.3, 32.7, 32.7, 31.6, 
29.7, 29.3, 28.2, 25.8, 24.5, 21.5, 18.1, 14.2, 12.7, –5.6, –5.63. 
(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-27-norcholest-5-en-25-oxo-21-oic acid, ethyl 
ester, cyclic 1,2-ethanediyl acetal (10). To THF (15 mL) containing 1 M LDA in THF (6 ml, 6 mmol) at –78 °C was added 
steroid 9 (1.1 g, 2.1 mmol) dissolved in THF (5 mL) and the reaction was stirred at -78 °C for 1 h. To the HMPA (1 mL) 
was then added and the reaction darkened in color. Stirring was continued at -78 °C for 10 minutes. To that solution was 
added 2-(3-iodopropyl)-2-methyl-[1,3]dioxolane  (2.04 g, 8 mmol) in THF (4 mL) and the reaction was stirred at -78 °C for 
1 h. The reaction was slowly allowed to warm to room temperature and stirring at room temperature was continued for 12 
h.  The reaction was quenched by adding saturated aqueous NH4Cl solution and the product was extracted into EtOAc. The 
combined organic extracts were washed with brine, dried over anhydrous Na2SO4 and the solvent removed under reduced 
pressure to give a solid. The crude product was purified by flash column chromatography (silica gel eluted with 10-20% 
EtOAc in hexane to give steroid 10 (1.25 g, 90%) which had: 1H NMR(400 MHz, CDCl3) δ 5.54 (b s, 1H), 4.67 (s, 2H), 
4.12 (m, 2H), 3.91 (m, 4H),  3.72 (d, J = 10.9 Hz, 1H), 3.56 (d, J = 10. 5 Hz, 1H), 3.43 (m, 1H), 3.36 (s, 3H), 1.28 (s, 3H), 
1.26 (t, J = 7.1 Hz, 3H), 0.85 (s, 9H), 0.72 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 176.1, 136.6, 
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125.1, 109.9, 94.6, 76.6, 64.6, 64.5, 63.1, 59.7, 56.6, 55.1, 52.5, 50.4, 47.3, 42.1, 41.4, 39.9, 38.9, 37.9, 32.7, 32.2, 31.5, 
29.3, 27.1, 25.8 (3 X C), 23.7, 23.7, 21.8, 21.6, 18.1, 14.2, 12.3, –5.66 (2 X C). 
(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-21-hydroxy-3-(methoxymethoxy)-27-norcholest-5-en-25-one, cyclic 
1,2-ethanediyl acetal (11). To a cold (0 °C) diethyl ether (10 mL) solution of steroid 10 (520 mg, 0.78 mmol) was added a 
2 M THF solution of LiAlH4 (2 mL, 4 mmol) and the reaction was stirred at room temperature for 4 h. The reaction mixture 
was cooled and water (0.5 mL) was added in small drops and the mixture was stirred for 20 min. To that mixture, 5 M 
aqueous NaOH (2 mL) was added and the mixture was stirred for 20 min. To the mixture was added water (2 mL) and 
stirring was continued for 1 h. The supernatant ethereal solution was decanted, dried over anhydrous Na2SO4 and the solvent 
removed under reduced pressure to give an oil. The crude product was purified by column chromatography (silica gel eluted 
with 20-30% EtOAc in hexane) to yield steroid 11 (450 mg, 93%): 1H NMR(400 MHz, CHCl3) δ 5.55 (b s, 1H), 4.69 (s, 
2H), 3.94 (m, 4H), 3.74 (d, J = 10.6 Hz, 1H), 3.69 (m, 2H), 3.58 (d, J = 10.6 Hz, 1H), 3.47 (m, 1H), 3.37 (s, 3H), 1.32 (s, 
3H), 0.87 (s, 9H), 0.87 (s, 3H), 0.04 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 136.6, 125.2, 110.1, 94.6, 76.6, 
64.6, 63.0, 62.5, 57.2, 55.2, 50.5, 50.2, 42.4, 42.2, 41.5, 39.9, 39.6, 39.5, 32.7, 32.6, 31.5, 29.5, 29.3, 27.7, 25.8, 24.1, 23.7, 
21.8, 20.7, 18.1, 12.4, –5.61, –5.63. 
(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-21-[(methylsulfonyl)oxy]-27-norcholest-5-en-
25-one, cyclic 1,2-ethanediyl acetal (12). To a CH2Cl2 solution (8 mL) of steroid 11 (400mg, 0.64 mmol) were added 
triethyl amine (1 mL) followed by mesyl chloride (0.16 mL, 2 mmol) and the reaction was stirred at room temperature for 
2 h. The reaction was quenched with aqueous saturated NaHCO3 (5 mL) and the biphasic solution was allowed to stir for 
30 min. The product was extracted into CH2Cl2 and the combined organic layers were washed with brine, dried over 
anhydrous Na2SO4 and the solvent removed under reduced pressure to give an oil. The crude product was purified by flash 
column chromatography (silica gel eluted with 20-30% EtOAc in hexane) to give steroid 12 (445 mg, 99%) which had: 1H 
NMR(400 MHz, CDCl3) δ 5.53 (b s, 1H), 4.69 (s, 2H), 4.35 (m, 1H), 4.18 (m, 1H), 3.74 (d, J = 10.6 Hz, 1H), 3.56 (d, J = 
10.6 Hz 1H), 3.46 (m, 1H), 3.35 (s, 3H), 2.99 (s, 3H), 1.29 (s, 3H), 0.86 (s, 9H), 0.72 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H); 13C 
NMR(100 MHz, CDCl3) δ 136.4, 125.0, 109.8, 94.6, 76.5, 70.1, 64.5, 63.1, 57.0, 55.1, 50.3, 49.9, 42.2, 41.3, 39.8, 39.6, 
39.4, 39.3, 37.2, 32.7, 32.6, 31.3, 29.3, 29.21, 27.4, 25.8 (3 X C), 23.9, 23.7, 21.7, 20.0, 18.1, 12.4, –5.7 (2 X C). 
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(3β)-19-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-(methoxymethoxy)-27-norcholest-5-en-25-one, cyclic 1,2-
ethanediyl acetal (13). To a cold (0 °C) diethyl ether (10 mL) solution of steroid 12 (350 mg, 0.50 mmol) was added a 2 
M THF solution of LiAlH4 (2 mL, 4mmol) and the reaction was stirred at room temperature for 4 h. The reaction mixture 
was cooled and water (0.5 mL) was added in small drops and the mixture was stirred for 20 min. To that mixture, 5 M 
aqueous NaOH (2 mL) was added and the mixture was stirred for 20 min. To that solution was added water (2 mL) and 
stirring was continued for 1 h. The supernatant ethereal solution was decanted, dried over anhydrous Na2SO4 and the solvent 
removed under reduced pressure to give an oil. The crude product was purified by flash column chromatography (silica gel 
eluted with 10-15% EtOAc in hexane) to yield  steroid 13 (290 mg, 96%) which had: 1H NMR(400 MHz, CDCl3) δ 5.54 (b 
s, 1H), 4.68 (s, 2H), 3.93 (m, 4H), 3.73 (d, J = 10.6 Hz, 1H), 3.58 (d, J = 10.6 Hz, 1H), 3.45 (m, 1H), 3.36 (s, 3H), 1.31 (s, 
3H), 0.87 (s, 9H), 0.70 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 136.6, 125.2, 110.2, 94.6, 76.6, 
64.6, 64.5, 63.0, 57.3, 56.0, 55.1, 50.5, 42.5, 41.4, 40.2, 39.9, 39.6, 36.1, 35.7, 32.7, 32.6, 31.6, 30.3, 29.3, 28.2, 25.8 (3 X 
C), 24.2, 23.7, 21.8, 20.6, 18.6, 18.1, 12.1,  –5.63 (2 X C). 
(3β)-19-Hydroxy-3-(methoxymethoxy)-27-norcholest-5-en-25-one, cyclic 1,2-ethanediyl acetal (14). Steroid 13 (121 
mg, 0.2 mmol) and 1 M tetra t-butylammonium fluoride in THF (1 mL) and THF (8 mL) were heated at reflux for 1h.  The 
reaction was cooled, diluted with water and the product extracted into CH2Cl2. The combined CH2Cl2 extracts were dried 
over anhydrous Na2SO4 and the solvent removed under reduced pressure to give a crude oil, which was purified by flash 
column chromatography (silica gel) to give steroid 14 (90 mg, 92%) which had: 1H NMR(400 MHz, CDCl3) δ 5.73 (b s, 
1H), 4.67 (s, 2H), 3.92 (m, 4H), 3.83 (d, J = 10.6 Hz, 1H), 3.58 (d, J = 10.9 Hz, 1H), 3.46 (m, 1H), 3.35 (s, 3H), 1.30 (s, 
3H), 0.91 (d, J = 7 Hz, 3H), 0.72 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 135.5, 127.3, 110.2, 94.7, 76.5, 64.5, 62.7, 57.6, 
56.0, 55.1, 50.4, 42.5, 41.7, 40.0, 39.6, 39.6, 36.1, 35.7, 33.33, 33.29, 31.2, 29.4, 29.3, 28.2, 25.6, 24.0, 23.7, 21.7, 20.6, 
18.6, 12.2. 
(3β)-25,25-[1,2-Ethanediylbis(oxy)]-3-(methoxymethoxy)-27-norcholest-5-en-19-al (15). Steroid 14 (49 mg, 0.1 mmol), 
pyridinium chlorochromate (86 mg, 0.4 mmol) and CH2Cl2 (8 mL) were stirred at room temperature for 3 h. The mixture 
was diluted with hexane (10 mL) and the supernatant liquid was passed through a silica gel column (eluted with 25-30% 
EtOAc in hexane) to give steroid 15 (39 mg, 80%) which had: 1H NMR(400 MHz, CDCl3) δ 9.65 (s, 1H), 5.84 (b s, 1H), 
4.65 (s, 2H), 3.92 (m, 4H), 3.41 (m, 1H), 3.34 (s, 3H), 1.30 (s, 3H), 0.89 (d, J = 6.7 Hz, 3H), 0.61 (s, 3H); 13C NMR(100 
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MHz, CDCl3) δ 205.3, 132.6, 127.5, 110.1, 94.7, 75.9, 64.6, 64.6, 56.4, 55.9, 55.1, 53.7, 48.9, 42.2, 41.0, 39.6, 39.6, 36.0, 
35.6, 32.9, 31.2, 30.4, 29.9, 28.1, 23.9, 23.7, 22.2, 20.5, 18.6, 11.8. 
(3β)-10-Ethynyl-3-(methoxymethoxy)-19,27-dinorcholest-5-en-25-one, cyclic 1,2-ethanediyl acetal (16). To a stirred 
suspension of chloromethyl triphenyl phosphonium chloride (347 mg, 1mmol) in THF (6 ml) was added 2.5 M n-butyl 
lithium in hexane (0.4 ml, 1 mmol) and the reaction was refluxed for 30 min. The reaction was cooled, a THF solution (3 
mL) of steroid 15 (39 mg, 0.08 mmol) was added and the reaction was heated to reflux for another 2 h. The reaction mixture 
was cooled, quenched with saturated aqueous NH4Cl and the product extracted into EtOAc. The combined organic extracts 
were washed with brine, dried over anhydrous Na2SO4 and the solvent removed to give an oil. The crude product was 
purified by flash column chromatography (silica gel eluted with 10-25% EtOAc in hexane) to give the 10-chloroalkene (–
CH=CHCl), which was immediately subjected to elimination without any characterization.  
To a cold (-78 °C) solution of n-butyl lithium (6 mL, 2.5 mmol in THF), was added the crude 10-chloroalkene in THF (3 
mL) and the reaction was slowly warmed to room temperature over a period of 40 min and stirred at room temperature for 
another 15 min. The reaction was cooled, carefully quenched with cold water and the product extracted into EtOAc. The 
combined EtOAc extracts were washed with brine, dried over anhydrous Na2SO4 and the solvent removed under reduced 
pressure to give an oil. The crude product was purified by flash column chromatography (silica gel eluted with 10-20% 
EtOAc in hexane) to give steroid 16 (21 mg, 55 %) which had: 1H NMR(400 MHz, CDCl3) δ 5.48 (b s, 1H), 4.70(s, 2H), 
3.94 (m, 4H), 3.43 (m, 1H), 3.38 (s, 3H), 1.32 (s, 3H), 0.94 (d, J = 6.3 Hz, 3H), 0.72 (s, 3H); 13C NMR(100 MHz, CDCl3) 
δ 136.8, 123.3, 110.2, 94.7, 87.0, 76.0, 72.0, 64.6, 56.0, 55.8, 55.2, 48.2, 42.4, 40.3, 39.7, 39.7, 39.3, 36.1, 35.7, 35.7, 33.2, 
31.7, 29.5, 28.2, 24.2, 23.7, 22.7, 20.6, 18.6, 11.7. 
(3β)-10-Ethynyl-3-(methoxymethoxy)-19,27-dinorcholest-5-en-25-one (17). A mixture of steroid 16l (20 mg), acetone 
(5 mL) and PTSA (20 mg) was stirred at room temperature for 2 h. The reaction was made basic with aqueous NaHCO3 and 
the acetone was removed. The residue was diluted with water and the product was extracted into CH2Cl2. The combined 
extracts were dried over anhydrous Na2SO4 and the solvent removed under reduced pressure to give an oil which was 
purified by flash column chromatography (silica gel eluted with 10-20% EtOAc in hexane) to give steroid 17 (18 mg, 99%) 
which had: 1H NMR(400 MHz, CDCl3) δ 5.48 (b s, 1H), 4.70(s, 2H), 3.43 (m, 1H), 3.38 (s, 3H), 2.26 (s, 1H), 2.14 (s, 3H), 
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0.94 (d, J = 6.3 Hz, 3H), 0.72 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 209.4, 136.8, 123.2, 94.7, 87.0, 76.0, 72.0, 55.8, 55.7, 
55.2, 48.2, 44.3, 42.4, 40.3, 39.6, 39.3, 35.7, 35.6, 35.4, 33.2, 31.6, 29.9, 29.7, 29.5, 28.2, 24.2, 22.6, 20.3, 18.6, 11.7. 
(3β)-25-Azi-10-ethynyl-3-(methoxymethoxy)-19,27-dinorcholest-5-ene (18). Steroid 17 (18 mg, 0.04 mmol) and 7 M 
ammonia in MeOH(4 mL) was stirred at room temperature under a nitrogen atmosphere for 4 h. Hydroxylamine-O-sulfonic 
acid (4.5 mg, 0.04 mmol) dissolved in MeOH (1 mL) was added and the resulting mixture was stirred at room temperature 
for 16 h. The solid floating in the solution was removed by filtration and the filter-cake was washed with MeOH. The solvent 
from the combined filtrate and the washings was removed under reduced pressure to give the intermediate 20-diaziridine as 
a residue which was not characterized and was immediately converted to steroid 18 as described below.  
The crude 20-diaziridine was dissolved in CH2Cl2 (5 mL) and triethyl amine (0.2 mL) was added to the solution. To the 
stirred solution was added in small portions I2 (50 mg) dissolved in CH2Cl2 (2 mL) until a brown color persisted. After few 
min, a few drops of 5% aqueous sodium thiosulfate was added to decolorize the solution and the resulting mixture was 
diluted with water (10 mL) and the product extracted into CH2Cl2 (3 x 10 mL). The combined extracts were dried over 
anhydrous Na2SO4 and the solvent removed under reduced pressure to give an oil. The crude product was purified by flash 
column chromatography (silica gel eluted with 5-15% EtOAc in hexane) to give steroid 18 (8 mg, 44%) as an off-white 
solid which had: 1H NMR(400 MHz, CDCl3) δ 5.48 (b s, 1H), 4.70(s, 2H), 3.42 (m, 1H), 3.38 (s, 3H), 2.26 (s, 1H), 1.00 (s, 
3H), 0.91 (d, J = 6.2 Hz, 3H), 0.72 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 136.8, 123.3, 110.0, 94.7, 87.0, 76.0, 72.0, 55.8, 
55.8, 55.2, 48.2, 40.3, 39.6, 39.3, 35.7, 35.6, 35.5, 34.7, 33.2, 31.7, 29.5, 28.2, 25.9, 24.2, 22.6, 20.6, 20.0, 18.6, 11.7. 
(3β)-25-Azi-10-ethynyl-19,27-dinorcholest-5-en-3-ol (19, KK-175). Steroid 18 (8 mg, 0.017 mmol) and 10% dry HCl in 
MeOH (5 mL) was stirred at room temperature for 4 h. The reaction mixture was carefully neutralized by adding aqueous 
NaHCO3 and the product was extracted into CH2Cl2 (3 x 25 mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and the solvent removed under reduced pressure to give an oil which was purified by flash column chromatography 
(silica gel eluted with 20- 30% EtOAc in hexane) to give steroid 19 (KK-175, 6 mg, 83%) which had: 1H NMR (400 MHz, 
CDCl3) δ 5.48 (b s, 1H), 3.51 (m, 1H), 2.26 (s, 1H), 0.99 (s, 3H), 0.91 (d, J = 6.2 Hz, 3H), 0.71 (s, 3H); 13C NMR(100 MHz, 
CDCl3) δ 136.7, 123.3, 87.1, 72.0, 70.9, 55.8, 55.8, 48.1, 42.4, 40.0, 39.3, 35.7, 35.6, 35.5, 34.7, 33.2, 32.3, 31.6, 28.2, 26.0, 
24.2, 22.7, 20.5, 20.0, 18.6, 11.9; IR(film, cm–1) 3427, 2937, 2865, 1585, 1464. 
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(3β,5α)-20-(4-Methyl-5-hexyn-1-yl)-spiro[pregnane-7,3’-[3H]diazirin]-3-ol, oleic acid ester (LKM-39). LKM-38 (20 
mg, 0.047 mmol), prepared as previously described (Science, 2017, 355, 1306; supplemental material), oleic acid (22 µL, 
0.071 mmol) and DMAP (9 mg, 0.071 mmol) were added to CH2Cl2 (5 mL) at 0 °C. N,N'-dicyclohexylcarbodiimide (11.3 
mg, 0.055 mmol) was dissolved in CH2Cl2 (0.1 mL) and added dropwise. The reaction was brought to room temperature 
and stirred for 16 h. Upon completion the reaction mixture was diluted with CH2Cl2 (10 mL), filtered, washed with 1 N 
HCl (5 mL), water (5 mL) and sat. aqueous NaHCO3 (5 mL). The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (silica gel eluted with EtOAc in 
hexane, gradient elution), to yield the product LKM-39 as a colorless oil (29 mg 0.042 mmol, 90%) which had: 1H NMR 
(400 MHz, CDCl3) δ 5.34 (m, 2H), 4.72 (m, 1H), 2.43-2.35 (m, 1H), 2.25 (t, 2H, J = 7.6 Hz), 2.03 (d, 1H, J = 2.4 Hz, 
CCH), 1.16 (d, 3H, J = 6.8 Hz), 0.94 (s, 3H), 0.89-0.87 (m, 6H), 0.79-0.66 (m, 1H), 0.59 (s, 3H), 0.34-0.24 (m, 1H), -0.01 
(dd, 1H, J = 14.0 Hz, J = 3.2 Hz); 13C NMR (100 MHz, CDCl3) δ 173.5, 130.2, 129.9, 89.5, 72.9, 68.2, 54.6, 52.4, 50.0, 
43.4, 42.5, 38.9, 37.4, 37.3, 36.5, 36.0, 36.0, 35.8, 35.6, 34.9, 33.4, 32.2, 32.1, 30.0, 29.9, 29.7, 29.5, 29.4, 29.3, 29.3, 
28.1, 27.5, 27.4, 27.4, 25.9, 25.2, 25.0, 23.8, 22.9, 21.1, 21.1, 19.0, 14.3, 12.1, 11.6. 
 



















LKM-38 KK-209  
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(3β,5α)-20-(4-Methyl-5-hexyn-1-yl)-spiro[pregnane-7,3’-[3H]diazirin]-3-one (KK-209). LKM-38, (12 mg, 0.028 
mmol), prepared as previously described (Science, 2017, 355, 1306; supplemental material) and  PCC (21 mg, 0.1 mol) in 
dichloromethane (2 mL) were stirred at room temperature for 2 hr. Hexane (3 mL) was added and after stirring for few 
min the supernatant liquid was transferred to a silica gel column and eluted with 10-20% EtOAc in hexane to give the 
product (KK-209, 9 mg, 75%) as a white solid which had: 1H NMR (400 MHz, CDCl3) δ 2.5-0.8 (m), 1.16 (d, 3H, J = 7.0 
Hz), 1.12 (s, 3H), 0.89 (d, 3H, J = 6.7 Hz), 0.62 (s, 3H), 0.29 (m, 1H), 0.06 (m, 1H). 13C NMR (400 MHz, CDCl3) δ 
210.61, 89.31, 68.02, 54.29, 51.68, 49.66, 43.95, 43.68, 43.11, 38.63, 37.88, 37.79, 37.09, 36.97, 35.94, 35.89, 35.54, 
35.36, 31.75, 27.87, 25.66, 24.71, 23.60, 21.19, 20.90, 18.73, 11.94, 10.66. 
